LSTM Home > LSTM Research > LSTM Online Archive

β-lactamase expression induces collateral sensitivity in Escherichia coli

Tools

Herencias, Cristina, Alvaro-Llorente, Laura, Ramiro-Martinez, Paula, Fernandez-Calvet, Ariadna, Munoz-Cazalla, Ada, DelaDuente, Javier, Graf, Fabrice, Jaraba-Soto, Laura, Castillo-Polo, Juan Antonio, Canton, Rafael, San Millan, Alvaro and Rodriguez-Beltran, Jeronimo (2024) 'β-lactamase expression induces collateral sensitivity in Escherichia coli'. Nature Communications, Vol 15, e4731.

Preview

Text
β-lactamase expression induces collateral sensitivity in Escherichia coli.pdf - Published Version
Available under License Creative Commons Attribution.
Download (2MB) | Preview

Official URL: https://doi.org/10.1038/s41467-024-49122-2

Abstract

Major antibiotic groups are losing effectiveness due to the uncontrollable spread of antimicrobial resistance (AMR) genes. Among these, β-lactam resistance genes –encoding β-lactamases– stand as the most common resistance mechanism in Enterobacterales due to their frequent association with mobile genetic elements. In this context, novel approaches that counter mobile AMR are urgently needed. Collateral sensitivity (CS) occurs when the acquisition of resistance to one antibiotic increases susceptibility to another antibiotic and can be exploited to eliminate AMR selectively. However, most CS networks described so far emerge as a consequence of chromosomal mutations and cannot be leveraged to tackle mobile AMR. Here, we dissect the CS response elicited by the acquisition of a prevalent antibiotic resistance plasmid to reveal that the expression of the β-lactamase gene blaOXA-48 induces CS to colistin and azithromycin. We next show that other clinically relevant mobile β-lactamases produce similar CS responses in multiple, phylogenetically unrelated E. coli strains. Finally, by combining experiments with surveillance data comprising thousands of antibiotic susceptibility tests, we show that β-lactamase-induced CS is pervasive within Enterobacterales. These results highlight that the physiological side-effects of β-lactamases can be leveraged therapeutically, paving the way for the rational design of specific therapies to block mobile AMR or at least counteract their effects.

Item Type:

Article

Subjects:

QW Microbiology and Immunology > Bacteria > QW 138 Enterobacteriaceae
QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified.
WC Communicable Diseases > Infection. Bacterial Infections > Enteric Infections > WC 290 Escherichia coli infections

Repository link: